Industry News prev next

Sep 26 2006

Alcon's Travatan Z Solution Receives FDA Approval

posted by: Bud O'Leary, OD

On September 21, 2006, Alcon, Inc. announced that that the U.S. Food and Drug Administration (FDA) has approved TRAVATAN Z (travoprost ophthalmic solution) 0.004% for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, who are intolerant of or insufficiently responsive to other intraocular pressure lowering medications.

TRAVATAN Z is a new formulation that eliminates benzalkonium chloride (BAK) from Alcon’s existing TRAVATAN solution and replaces BAK with sofziatim, a robust ionic buffered preservative system that is gentle to the ocular surface. Alcon developed this BAK-free version of TRAVATAN because long-term use of topical solutions containing BAK may compromise the ocular surface and exacerbate conditions such as dry eye.

To read the full press release about TRAVATAN Z, click below.

Sudipta Ghosh - on Oct 22, 2006

I would like to receive some full text about the new approved drug Travatan Z

Janet Swartz, EdD - on Oct 23, 2006

Dr. Ghosh,

If you click on the Alcon logo on the lower right side of this website, it will bring you to Alcon's Travatan website where there is complete product information about Travatan Z.